Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Immunogenicity, Safety and Reactogenicity of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate Compared to Fluarix™ Administered Intramuscularly in Elderly Aged 60 Years and Above.

NCT00385840 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00385840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00385840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Immunogenicity, Safety and Reactogenicity of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate Compared to Fluarix™ Administered Intramuscularly in Elderly Aged 60 Years and Above.
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
October 20, 2006
Completion date
February 5, 2007
Enrollment
678 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

influenza